导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -1.50% | 2644/4773 |
| 近一周 | -2.25% | 1595/5462 |
| 近一月 | -4.12% | 2233/5421 |
| 近一季 | -7.14% | 2304/5209 |
| 近半年 | -2.34% | 1867/4920 |
| 近一年 | 0.90% | 2451/4366 |
| 近两年 | 45.60% | 1618/2954 |
| 近三年 | 26.81% | 1192/2253 |
| 成立以来 | 36.53% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.70% 3357/4961 |
12.36% 2189/5312 |
- - |
- - |
| 2025 | 19.81% 2178/4813 |
-0.98% 2510/3635 |
2.24% 1720/4076 |
18.24% 2323/4524 |
0.09% 2229/4813 |
| 2024 | 16.17% 839/3463 |
2.48% 770/2808 |
-1.15% 949/3014 |
16.64% 1393/3129 |
-1.69% 1793/3463 |
| 2023 | -9.81% 1232/2656 |
3.97% 1083/2280 |
-3.95% 980/2385 |
-2.77% 747/2515 |
-7.12% 2056/2655 |
| 2022 | -18.79% 760/2207 |
-13.34% 738/1919 |
6.26% 737/2016 |
-13.25% 867/2113 |
1.66% 1190/2208 |
| 2021 | -1.78% 818/1822 |
-2.68% 688/1255 |
4.55% 873/1330 |
-5.03% 765/1466 |
1.65% 848/1822 |
| 2020 | 32.81% 475/1250 |
-8.63% 624/1028 |
12.97% 658/1067 |
13.98% 304/1164 |
12.88% 417/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 国联安沪深300ETF联接C VS. 长安沪深300非周期A(740101) |